SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- A federal securities fraud class action lawsuit has been filed in the Eastern District of New York against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The lawsuit alleges that the telehealth company presented a misleadingly optimistic image of its financial health and growth prospects, which ultimately led to a dramatic stock price decline in August. The suit, Johnston v. LifeMD, Inc., is seeking to recover damages for investors that purchased LifeMD secu ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart visible in the background, on May 4, 2025, in Chongqing, China. Hims & Hers is an American telehealth company that provides personalized healthcare products and services for mental health, dermatology, sexual wellness, and primary care through a direct-to-consumer platform. (Photo illustration by Cheng Xin/Getty Ima ...

Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at $499 per month. Through LifeMD’s integration with NovoCare® Pharmacy, eligible self-pay and uninsured patients, as well as insured ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=169640&from=3 CLASS PERIOD: May 7, 2025 to Augus ...

SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- A new federal securities fraud class action lawsuit has been filed against LifeMD, Inc. (NASDAQ: LFMD) and its executives. The suit alleges the telehealth company presented a misleadingly optimistic picture of its financial health and growth, ultimately resulting in a dramatic stock price decline in August. The action was filed in the Eastern District of New York. The lawsuit, Johnston v. LifeMD, Inc., focuses on the period between May 7, 2025, and August 5, ...

人工智能在医疗行业的转型作用 - 人工智能正在以类似30年前互联网采用的方式改变世界 尤其对医疗行业产生重大变革[1] - 生成式和代理型人工智能帮助医生和护理团队提高诊断准确性 简化行政任务 并降低职业倦怠风险[2] - 93%的医生经常感到倦怠 随着人口老龄化加剧供需失衡 人工智能有助于弥合效率与个性化护理之间的差距[2] Hims & Hers Health (HIMS) 投资分析 - 作为远程医疗公司 HIMS在2025年表现优异 年内上涨121% 过去30天上涨29%[4] - 公司利用人工智能简化行政任务 包括分诊患者问题 自动化随访提醒和简化处方续订流程[5] - 股价现报53.86美元 较2月历史高点下跌约21% 两次在65美元附近遇到阻力 交易量高显示短线交易者主导价格[6] - Canaccord Genuity集团于9月12日重申买入评级 目标价68美元 分析师共识评级为持有[7] Tempus AI (TEM) 投资分析 - 公司应用人工智能和机器学习处理基因组 临床和分子数据 推动精准医疗发展[8] - 专注于肿瘤学领域 AI工具帮助医生定制癌症治疗方案 预测结果并识别实时临床试验机会[9] - 全球前20大制药公司中有19家使用Tempus数据进行药物发现 9月获得FDA 510(k)批准RNA测序设备xR IVD[10] - 2025年股价上涨128% 过去三个月上涨17% 空头兴趣超过25% 在89美元历史高点附近显示阻力[11] Boston Scientific (BSX) 投资分析 - 医疗设备公司利用人工智能简化数据处理需求 数字健康解决方案提升性能和临床结果[13] - 近期催化剂是FDA批准FARAPULSE脉冲场消融系统扩大适用范围 治疗近6000万人的特定心房颤动[14] - 2025年股价上涨约17% 与标普500指数表现基本一致 但难以突破52周高点[15] - 尽管分析师给予买入评级 但顶级研究分析师认为其他五只股票更具投资价值[16]

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY). The new fund aims to provide current income by utilizing options-based strategies related to Hims & Hers Health Inc (NYSE: HIMS), a prominent consumer health and wellness business.HIMS stock is showing exceptional strength. See if it is worth your attention here.Unlike other equity ETFs, HIYY does not actually invest in Hims & Hers shares. Instead, t ...

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade-long track record of helping patients a ...

Las Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States NationwideMesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company's decade-long track record of helping patients acc ...

Now Operating in 19 States NationwideLas Vegas, NV, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Cannabis Evaluations to Connecticut, Now Operating in 19 States Nationwide Mesquite, NV — September 26, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP today announced that its subsidiary PrestoDoctor, a leading telemedicine platform for medical cannabis evaluations, is expanding services to Connecticut. With this addition, PrestoDoctor now operates in 19 states across the United States, further extending the Company’s decade- ...